Blue Jet Healthcare Q3: Shares fall 9% as revenue drops, margin shrinks

Blue Jet Healthcare reported a mixed set of numbers for the quarter ended December 31, 2025, with profit rising sharply on a year-on-year basis, even as revenue and operating metrics declined.

Net profit stood at ₹99 crore in Q3 FY26, up 59.6% from ₹40 crore in the corresponding quarter last year. However, revenue from operations fell 39.6% to ₹192.4 crore, compared with ₹318.3 crore a year ago.

Operating performance also weakened during the quarter. EBITDA declined 62.2% year-on-year to ₹47 crore from ₹124 crore, while EBITDA margin narrowed to 24.3% from 39% in the year-ago period, reflecting pressure at the operating level.

The divergence between profit and operating metrics comes even as topline contraction and margin compression weighed on sentiment.

Following the earnings announcement, shares of Blue Jet Healthcare slipped sharply. The stock touched an intraday low of ₹397.45. As of 02:05 PM, it was trading at ₹402.90 on the NSE, down ₹38.70 or 8.76% for the day.

Also Read: Ipca Labs Q3 Results: Profit up 31%, margin expands as domestic and export sales grow

Blue Jet Healthcare is a speciality pharmaceutical and healthcare ingredient manufacturer, focused on contrast media intermediates, high-intensity sweeteners and pharmaceutical intermediates, catering to global markets.